A Phase II Study of Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors


Full Title

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (RTOG 1008)


The standard treatment for cancer of the salivary gland is surgery. Although surgery may have removed the cancer, some patients are at increased risk for recurrence. In these patients, radiation therapy after surgery is recommended.

The purpose of this study is to see if giving chemotherapy in addition to radiation after surgery is more effective than radiation alone in patients with high-risk salivary gland tumors. Patients will be randomly assigned to receive radiation after surgery or radiation plus the anticancer drug cisplatin, given concurrently.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a malignant salivary gland tumor with a high risk of recurrence, such as high-grade mucoepidermoid carcinoma, salivary duct carcinoma, or high-grade adenocarcinoma.
  • Patients’ tumors must have been surgically removed within 8 weeks of entering the study.
  • Patients may not have had prior chemotherapy or radiation therapy for salivary gland cancer.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Nancy Lee at 212-639-3341.